ClinicalTrials.Veeva

Menu
A

Allergy Research Canada, Inc. | Niagara Falls, Canada

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Rocatinlimab
Baricitinib
Upadacitinib
LY3009104
Dupilumab
AMG 451
EVO756

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 12 total trials

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up)

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Topical therapies applied over the skin...

Enrolling
Atopic Dermatitis
Drug: Upadacitinib
Drug: Dupilumab

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Active, not recruiting
Atopic Dermatitis
Other: Placebo
Drug: Rocatinlimab

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent parti...

Active, not recruiting
Atopic Dermatitis
Drug: Rocatinlimab
Drug: Placebo

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Placebo for Upadacitinib

The primary objective of this study is to assess successful self-administration of rocatinlimab subcutaneously using devices for injection.

Active, not recruiting
Atopic Dermatitis
Combination Product: Rocatinlimab AI
Combination Product: Rocatinlimab Prefilled Syringe

This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe chronic spontaneous urticaria (CSU).

Enrolling
Chronic Spontaneous Urticaria
Drug: EVO756
Drug: Placebo control

Trial sponsors

Amgen logo
AbbVie logo
Lilly logo
E
Janssen (J&J Innovative Medicine) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems